Navigation Links
Personalized Medicine and Innovative Pharmaceuticals

Personalized medicine is creating quite a revolution of sorts. A clue into what might be the norm, years from now, personalized medicines will aim at reducing// or totally obliterating the side-effects by evolving medicines that are tailor –made to a person’s genetic information. Indeed this will be a whole new story in the development of drugs.

Amalia M. Issa, a pharmacologist and clinical epidemiologist is the director of the Program in Personalized Medicine and Targeted Therapeutics at the Abramson Family Center for the Future of Health, a joint initiative between UH and The Methodist Hospital Research Institute. The discussion on personalized medicine will focus on initiatives to develop drugs that are customized for an individual patient's particular condition and side-effects profile, and the process required for innovative pharmaceuticals. The main issues facing the scientists and pharmaceutical industry will also receive focus during the discussion.

Source: Eureka
'"/>




Page: 1

Related medicine news :

1. Advent of New, More Effective and Personalized Medicines
2. Personalized Treatments For Obesity Planned
3. Personalized Genetics: Unraveling the Secret Code to Good Health.
4. Personalized Genetic Testing Will Call the Shots!
5. Nobel Prize for Medicine shared by Three scientists
6. Prince Charles lends support to Alternative Medicine
7. Healthy Medicine Or Harmful Intoxicant?
8. Medicines on the move
9. A surge in Lifestyle Medicine
10. Does Your Prescription Have An Inappropriate Medicine?
11. The Use Of Alternative Medicine On The Rise
Post Your Comments:
(Date:5/16/2008)...cal trials presented by Calpis Co., Ltd. at the Am...Annual Scientific Meeting and Exposition (ASH 2008...y supplement AmealPeptide reduces blood pressure i...D (Achieve Hypertension Efficacy with AmealPeptide...tive, Two-phase Randomized, Open-Label, Blinded En...
(Date:5/16/2008)... -- Superior launch strategies,allow best-in-class...,crowded markets. To secure "share of voice" for a...ptake strategies to support business needs and,ens...l companies achieve,attention in the market during...., "Best Practices for Winning Product Launch Suc...
(Date:5/16/2008)...d Information Technology That, Optimizes Cardiolo...ases Efficiency, SE...ced clinical and,information technology (IT) for t...www.siemens.com/healthcare ) will demonstrate the ...iology and cardiology workflow and image,processin...
(Date:5/16/2008)...PRNewswire-FirstCall/ -- BMP,Sunstone Corporation ...and,distribution pharmaceutical companies, today a...owing conferences:, (1) The Roth Annual China D...David Gao, Chief Executive Officer of the Company,... 2008, at 4:40 pm local time at the Regent Ho...
Breaking Medicine News(10 mins):Health News:Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials 2Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 3Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 4Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 5Health News:BMP Sunstone Announces Participation in May Investor Conferences 2
...equires continuing medical care and patient self-m... and to reduce the risk of long-term complications...r, primary care practitioners are confronted with ...th signs of diabetic nephropathy. Undiagnosed chro...
...ient myth that coco bean can be used to treat diar...n chemicals that can limit the development of flui...t diarrhea dates back to as early as 16th century ...ultures. Until now, very little has been known reg...
... become very easy and cheap compared to other coun...of clinical research to India. Outsourcing in the...cs and development of India, but Outsourcing in /...India, as humans are becoming a source of experime...
...ied women is having more trouble due to her sexual... women and the report finds out that single men is...n compared to married women. // Catherine Mercer...r for Sexual Health and HIV, said. "That is, withi...
Other Medicine News:
(Date:5/16/2008)...Newswire-FirstCall/ -- Pulmo BioTech Inc. (OTC,Bul... methodology and,purpose of its Phase I Human Tria... for the diagnosis of Pulmonary Embolism and Pulmo...by the Pulmo BioTech subsidiary,PulmoScience Inc....the Use,of PulmoBind for Molecular Imaging of the ...
(Date:5/16/2008)...ay 16 /- Data from three studies,eval...moglobin (Hb) levels,and the rate of blood transfu...ons on reimbursement for erythropoiesis-stimulatin...,s blood supply, will be presented at the,American...g later this,month. The meeting will take place in...
(Date:5/16/2008)...bles First-Ever PEGylation of a Small Molecule wit...ity, SAN CARLOS, Calif., May 16 /PRNewswire-First...unced initial results today from a Phase 1,study o...significant,anti-tumor activity in patients with r...s that Nektar,s small molecule PEGylation technolo...
(Date:5/16/2008)...Dual Mechanism May Offer Novel Approach to Blood ...ORLEANS, May 16 /- Pharmaco... and development of novel small,molecule therapeut...lass,Dual Acting Receptor Antagonist (DARA), showe...ons in a Phase 2a study in patients with mild to,m...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Alticors 2007 Global Sales Top 247 Billion 11136 1Alticors 2007 Global Sales Top 247 Billion 11136 2Alticors 2007 Global Sales Top 247 Billion 11136 3Alticors 2007 Global Sales Top 247 Billion 11136 4Alticors 2007 Global Sales Top 247 Billion 11136 5Alticors 2007 Global Sales Top 247 Billion 11136 6Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 1Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 2Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 3AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 1AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 2AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 3HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 1HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 2
...SS WIRE)--Jul 9, 2007 - ZIOPHARM,Oncology, Inc. (N...from an ongoing phase II trial of ZIO-201 (isophos... patients was presented at the,European Society of...07 in Lugano, Switzerland. The abstract entitled, ...coma," was presented by,Rashmi Chugh, MD, a Princi...
...--Jul 9, 2007 - TransPharma Medical,Ltd., a specia...ent,and commercialization of drug products utilizi...technology, announced today,promising results of i...y and pharmacokinetic profile of its ViaDerm-hPTH ... A seven day, repeated dose application, parallel ...
Other Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3
We have water perfused manometric catheters for esophageal, anorectal and vector volume diagnostic tests. All Medtronic Water Perfused Catheters are made using clear, medical grade PVC tubing. For pr
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
...dtronic offers a family of single-use products to ...or you. This single-use catheter reduces cross-con...e risk of infection and, because cleaning is elimi...have water perfused manometric catheters for esoph...
Medicine Products: